Pfizer well-positioned for Wyeth merger

At the company's annual meeting of shareholders, chief executive Jeffrey Kindler said US drug giant Pfizer has streamlined operations, reduced  bureaucracy, set clear expectations and increased accountability, which  has better positioned the company to combine with Wyeth.

"The combination of Pfizer and Wyeth will allow us to advance each and  every one of the key growth strategies that will drive our success in  the years ahead," Mr Kindler noted. "Pfizer plus Wyeth will help us  extend our leadership in global health care in both developed and  developing markets. This includes leadership in primary and specialty  care; in vaccines, biologics and small molecules; and in animal health,  consumer health and nutritionals," he added.